Global Cushing's Syndrome Market - 2024-2031

Global Cushing's Syndrome Market - 2024-2031

Global Cushing’s syndrome market reached US$ 146.5 million in 2023 and is expected to reach US$ 291.1 million by 2031 growing with a CAGR of 8.96% during the forecast period 2024-2031.

Cushing’s syndrome which is also termed as hypercortisolism is characterized by excessive adrenocorticotropic hormone (ACTH) production by the anterior pituitary that leads to the release of an excess of cortisol from the adrenal glands. Common signs of Cushing’s syndrome include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks.

The disease is most common among adults between the ages of 30–50, and it affects women three times more often than men. Women with Cushing's syndrome may experience a variety of health issues including menstrual problems, difficulty becoming pregnant, excess male hormones (androgens), primarily testosterone, which can cause hirsutism (growth of coarse body hair in a male pattern), oily skin, and acne.

The global Cushing’s syndrome market has witnessed significant growth in recent years due to the adoption of medications to control cortisol production. Ketoconazole, Osilodrostat (Isturisa), Mitotane (Lysodren), Levoketoconazole (Recorlev), and Metyrapone (Metopirone) are commonly used medications to treat Cushing’s syndrome.

Market Dynamics: Drivers

Increasing research and developments and rising fda approvals for cushing's syndrome treatment

The demand for the global Cushing’s syndrome market is driven by multiple factors. One of the primary factors is the advanced research and developments in treating Cushing's syndrome help to drive this market growth.

For instance, in August 2023, Sparrow Pharmaceuticals announced the first patient has elected to enroll in the open-label extension phase of the RESCUE trial which is a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor for the treatment of ACTH-dependent Cushing’s syndrome. RESCUE is evaluating the pharmacologic effect, efficacy, and safety of SPI-62 in patients with adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome.

Additionally, in August 2023, Corcept Therapeutics announced the drug Relacorilant is under clinical development in Phase III for Cushing’s Syndrome. It is a small molecule administered orally and the drug candidate is a next-generation cortisol modulator that targets glucocorticoid receptor II (GR-II).

Moreover, the increase in treatment approvals by regulatory bodies helps to drive this market growth. In January 2022, PANTHERx Rare announced that it had been selected by Xeris Pharmaceuticals, Inc. as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication called Recorlev (levoketoconazole). Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Restraints

Factors such as the high cost of the treatment, limited treatment options, complications associated with the treatment, stringent regulatory approvals, and lack of awareness & diagnosis among people are expected to hamper the market.

Segment Analysis

The global Cushing's syndrome market is segmented based on type, treatment, end users, and region.

The medications segment accounted for approximately 49.7% of the global Cushing's syndrome market share

The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of drugs globally have contributed to the growing demand for Cushing's syndrome treatment. For instance, according to clinicalTrials.gov, in April 2023, Crinetics Pharmaceuticals Inc. conducted a clinical trial on a study to evaluate the safety and pk of CRN04894 for the treatment of Cushing's syndrome.

Moreover, government funding and research & development in the medication of Cushing syndrome would drive this segment growth. For instance, in April 2023, Sparrow Pharmaceuticals announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.

In addition, key players in the industry partnerships & collaborations and government awareness programs would propel this market growth. For instance, in December 2022, Corcept Therapeutics Incorporated announced that it had entered into an agreement with Hikma Pharmaceuticals USA Inc. (""Hikma"") resolving patent litigation related to Korlym, Corcept’s medication for the treatment of patients with Cushing’s syndrome.

Also, in April 2023, Recordati Rare Diseases announced the launch of #thisCushing, a global awareness campaign designed with award-winning photographers and internationally recognized endocrinologists

Geographical Analysis

North America accounted for approximately 41.4% of the global Cushing syndrome market share

North America region is expected to hold the largest market share over the forecast period. Cushing's Disease (CD) is caused by a pituitary tumor that signals the adrenal glands to release too much of the hormone cortisol. Cushing's Syndrome can be caused by many sources including a tumor in the adrenal gland or lung, certain steroid shots and medications, even alcoholism and severe depression.

As per Ubie Symptoms Checker in April 2024, CD is a rare disease, impacting about 10 to 15 people per million in the US each year. CS from an endogenous (inside the body) source is also rare, though it impacts about 40 to 50 per million per year in the US.

In this region, major players' strategies such as partnerships & collaborations, and drug approvals would drive this market growth. For instance, in April 2024, Ubie announced a partnership aimed at shortening the time to diagnosis for patients with Cushing's Disease (CD) and Cushing's Syndrome (CS).

Also, in February 2023, the U.S. Food and Drug Administration (FDA) granted Xeris Pharmaceuticals orphan-drug exclusivity for Recorlev (levoketoconazole), its approved treatment for adults with endogenous Cushing’s syndrome. Recorlev is the pure 2S,4R enantiomer of ketoconazole, and Recorlev has demonstrated in two successful Phase 3 studies to significantly reduce mean urinary-free cortisol.

Market Segmentation

By Type
• Exogenous Cushing's Syndrome
• Endogenous Cushing's Syndrome

By Treatment
• Medications
Mifepristone
Pasireotide
Ketoconazole
Mitotane
Metyrapone
• Surgery
• Radiation Therapy
• Chemotherapy
• Others

By End Users
• Hospitals
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the Cushing’s syndrome market include Corcept Therapeutics, Piramal Pharma Solutions, LGM Pharma, Sigma Aldrich, Tocris Bioscience, Tecoland Corporation, Sparrow Pharmaceuticals, Novartis AG, Xeris Biopharma, and Zhejiang Supor Pharmaceuticals Co. Ltd. among others.

Key Developments

In February 2023, Bristol Practice unveiled a radical 3D printing guide to aid Cushing’s disease surgery. The system was developed through funding from a CVS Group research program.

In January 2022, Xeris Biopharma announced that Recorlev (levoketoconazole) is now commercially available for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.

Why Purchase the Report?
• To visualize the global Cushing's syndrome market segmentation based on type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Cushing's syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Cushing's syndrome market report would provide approximately 70 tables, 69 figures, and 181 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies